

Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 315980, 6 pages
<http://dx.doi.org/10.1155/2013/315980>



Research Article

Genotyping of *CYP2C9* and *VKORC1* in the Arabic Population of Al-Ahsa, Saudi Arabia

Abdullah M. Alzahrani,¹ Georgia Ragia,² Hamza Hanieh,¹ and Vangelis G. Manolopoulos²

¹ Biological Sciences Department, College of Science, King Faisal University, Hofouf 31982, Saudi Arabia

² Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece

Correspondence should be addressed to Abdullah M. Alzahrani; aalzahra@kfu.edu.sa

Received 28 October 2012; Revised 17 January 2013; Accepted 3 February 2013

Academic Editor: M. Ilyas Kamboh

Copyright © 2013 Abdullah M. Alzahrani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Polymorphisms in the genes encoding *CYP2C9* enzyme and *VKORC1* reductase significantly influence the dose variability of coumarinic oral anticoagulants (COAs). Substantial inter- and intraethnic variability exists in the frequencies of *CYP2C9**2 and *3 and *VKORC1* -1639A alleles. However, the prevalence of *CYP2C9* and *VKORC1* genetic variants is less characterized in Arab populations. A total of 131 healthy adult subjects from the Al-Ahsa region of Saudi Arabia were genotyped for the *CYP2C9**2 and *3 and *VKORC1* -1639G>A polymorphisms by PCR-RFLP method. The frequencies of the *CYP2C9**2 and *3 and *VKORC1* -1639A alleles were 13.3%, 2.3%, and 42.4%, respectively, with no subjects carrying 2 defective alleles. The frequencies of the *CYP2C9**3 and *VKORC1* -1639A alleles were significantly lower than those reported in different Arabian populations. None of the subjects with the *VKORC1* -1639AA genotype were carriers of *CYP2C9**1/*3 genotypes that lead to sensitivity to COAs therapy. The low frequency of the *CYP2C9**3 allele combined with the absence of subjects carrying 2 defective *CYP2C9* alleles suggests that, in this specific population, pharmacogenetic COAs dosing may mostly rely upon *VKORC1* genotyping.

1. Introduction

Pharmacogenomics is the first step towards personalized medicine and is a promising field of investigation that may explain some of the interindividual variations in responses to various classes of drugs [1, 2]. Pharmacogenomics can be applied to all fields of medicine. In particular, recent advances in genotype-phenotype associations in cardiology point towards the application of pharmacogenomics to oral coumarinic anticoagulants (COAs), including warfarin, acenocoumarol, and phenprocoumon, in routine clinical practice [3].

Among other factors, interindividual COAs dose variability is significantly influenced by variations in the genes encoding two enzymes: cytochrome P450 2C9 (*CYP2C9*), the enzyme that metabolizes COAs, and vitamin K epoxide reductase (*VKORC1*), the pharmacologic target of these drugs [3].

Polymorphisms in the *CYP2C9* gene seriously affect the enzymatic activity of the encoded *CYP2C9* protein. Based

on phenotype, populations can be divided into extensive (EM), intermediate (IM), and poor metabolizers (PM), and more than 35 different allelic variants have been identified in the *CYP2C9* gene [4]. Among these alleles, the *CYP2C9**2 (rs1799853) and *3 (rs1057910) variants, which reduce *CYP2C9* enzymatic activity, allow for the prediction of more than 85% of PMs [5]. In addition, it has recently been shown that *VKORC1* gene polymorphisms also affect COAs dosing requirements [6]. The *VKORC1* -1639G>A polymorphism (rs9923231) is located in the promoter of the *VKORC1* gene and results in reduced promoter activity and lower mRNA levels, which lead to lower levels of synthesized protein and eventually the reduced production of active clotting factors in subjects with the AA genotype [6].

Whereas the *CYP2C9**2 and *3 alleles affect coumarin pharmacokinetics, the *VKORC1* -1639G>A polymorphism affects the pharmacodynamic response to coumarins [3]. It has been reported that polymorphisms in the *CYP2C9* and *VKORC1* genes together account for 35%–50% of the variability in COAs dose requirements for initiation and

maintenance [7]. Moreover, carriers of the *CYP2C9**2 or *3 alleles and the *VKORC1* -1639G>A polymorphism are at higher risk for bleeding and require lower mean daily doses [3]. These associations between genotype and COAs response led the U.S. Food and Drug Administration (FDA) to release a warning in the warfarin insert to indicate the range of expected therapeutic warfarin dosages based on *CYP2C9* and *VKORC1* genotypes [8]. Furthermore, the clinical feasibility of incorporating *CYP2C9* and *VKORC1* genotyping-based COAs dosing regimens into routine clinical practice is being tested in large prospective clinical trials [9–11].

Substantial inter- and intraethnic variability in the frequencies of the *CYP2C9* and *VKORC1* alleles has been reported [5, 12]. The *CYP2C9**2 allele is absent in East Asian populations, whereas its frequency in African-Americans and Ethiopians has been estimated to be as low as 3.2% [5]. By contrast, a higher frequency of the *CYP2C9**2 allele (5%–19%) has been reported in Caucasians [5, 13]. Furthermore, the frequency of the *CYP2C9**3 allele is significantly lower in Asian populations (as low as 3.3%, compared to 4%–16% in Caucasians) [5, 13]. In Arabian populations, intraethnic variability in the frequency of the *CYP2C9**2 and *3 alleles has been reported, ranging from 7% to 21% and 3% to 9%, respectively [14–18]. In the case of the *VKORC1* -1639G>A polymorphism, interethnic variability in -1639AA frequency has also been reported [19]. Moreover, the -1639AA genotype, which is highly correlated with COAs sensitivity, is more common in Asian (frequency 80%) than Caucasian or African populations (estimated frequency 16%–25%) [19, 20]. Whereas the frequency of the -1639A COAs sensitivity allele ranges between 52% and 56% in the Arab populations studied to date [18, 21], no investigation of the *VKORC1* -1639G>A polymorphism in Saudi Arabians has been reported.

Few data are available concerning the prevalence of the *CYP2C9**2 and *3 alleles and the *VKORC1* -1639G>A polymorphism in distant populations of Saudi Arabia where social and in some areas religious beliefs favor consanguineous marriages and therefore limit genetic flow. In the Al-Ahsa region, which is part of the eastern province of Saudi Arabia, the rate of consanguineous marriage has been reported to be 59.1%, with marriages between first-degree relatives at 40% [22]. The reported inter- and intraethnic variability in the frequencies of the *CYP2C9**2 and *3 and *VKORC1* -1639A alleles was our rationale for studying the incidence of these variant alleles in the Al-Ahsa population. The results of this investigation will be critical for the coming era, in which genotype-guided dosing algorithms will be increasingly utilized to guide the prescription of COAs [9–11].

The aim of the present study was to investigate the frequency of the *CYP2C9**2 and *3 alleles and the *VKORC1* -1639G>A polymorphism as well as the number and percentages of individuals with genotypes predictive of COAs response in a representative sample of the population of Al-Ahsa, Saudi Arabia. We also sought to compare the data obtained with existing published data for other populations residing in a wider area of the Middle East.

2. Materials and Methods

2.1. Subjects. All participants were of Arabian origin and residents of the Al-Ahsa urban area, which is located on the east coast of Saudi Arabia. The study protocol was approved by the Ethics Committee of King Faisal University, Hofouf, Saudi Arabia. All of the study participants were nonrelative volunteers and provided informed consent. A total of 131 healthy adult subjects (70 males and 61 females) were genotyped to determine the frequencies of the *CYP2C9**2 and *3 alleles and the *VKORC1* -1639G>A polymorphism. The mean (\pm SD) age of the subjects was 25 (\pm 7) years (range: 19–52 years). The majority of the subjects (57%) reported to originate from a consanguineous marriage.

2.2. Genotyping. Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Germany) according to the manufacturer's instructions. All subjects were genotyped for the *CYP2C9**2 and *3 alleles and the *VKORC1* -1639G>A polymorphism using PCR-restriction fragment length polymorphism (RFLP) protocols, as previously described [13, 20]. PCR amplifications were performed in duplicate by two independent researchers in an MJ Research PTC-200 thermocycler (Watertown, MA, USA). To ensure the accuracy of the results, an internal positive control was utilized for each polymorphism (rare allele) in each PCR-RFLP run.

2.3. Statistics. Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 17.0 and are presented as the medians with 95% confidence intervals. Departure from the Hardy-Weinberg equilibrium was estimated using an exact 2-sided probability test using the formula provided by Weir [23]. Allele frequencies were compared to other ethnic population utilizing the two-tailed Fisher's exact test [24].

3. Results

The distributions of genotypes and alleles of *CYP2C9**2 and *3 and *VKORC1* -1639G>A polymorphisms in the studied population are shown in Table 1.

For the *CYP2C9**2 and *3 alleles, 90 subjects (68.7%) were genotyped as *CYP2C9**1/*1, 35 subjects (26.7%) as *CYP2C9**1/*2, and 6 subjects (4.6%) as *CYP2C9**1/*3. The frequency of the *CYP2C9**2 and *3 alleles was estimated at 13.3% and 2.3%, respectively. None of the subjects were found to be homozygous or combined heterozygous for the *CYP2C9**2 and *3 alleles (*CYP2C9**2/*2, *CYP2C9**2/*3, and *CYP2C9**3/*3 genotypes). The genotype-derived PM phenotype was absent in the study population, whereas 68.7% of the population was predicted to be EM and 31.3% to be IM.

For the *VKORC1* -1639G>A polymorphism, 49 subjects (37.4%) were genotyped as GG, 52 subjects (39.7%) as GA, and 30 subjects (22.9%) as AA. The frequency of the A allele was 42.7% (112 alleles). Consistent results for each genotype call were obtained by two researchers who performed the genotyping independently.

TABLE 1: Frequencies of the *CYP2C9**2 and *3 and *VKORC1* –1639G>A genotypes and alleles in a sample of the Saudi Arabian population (*n* = 131).

Genotypes and alleles	No. of individuals, relative frequency, and 95% confidence intervals	
	<i>n</i> (%)	95% CI
<i>CYP2C9</i> genotype		
<i>CYP2C9</i> *1/*1	90 (68.7)	60.4–76.2
<i>CYP2C9</i> *1/*2	35 (26.7)	19.7–34.7
<i>CYP2C9</i> *1/*3	6 (4.6)	1.9–9.2
<i>CYP2C9</i> *2/*2	0	—
<i>CYP2C9</i> *2/*3	0	—
<i>CYP2C9</i> *3/*3	0	—
<i>CYP2C9</i> allele		
<i>CYP2C9</i> *2	35 (13.3)	9.7–17.9
<i>CYP2C9</i> *3	6 (2.3)	1.0–4.7
<i>VKORC1</i> genotype		
GG	49 (37.4)	29.5–45.9
GA	52 (39.7)	31.6–48.2
AA	30 (22.9)	16.4–30.6
<i>VKORC1</i> allele		
G	150 (57.3)	51.2–63.1
A	112 (42.7)	36.9–48.8

TABLE 2: Combination of *CYP2C9* and *VKORC1* genotypes in a sample of the Saudi Arabian population (*n* = 131).

<i>CYP2C9</i> genotype	<i>VKORC1</i> genotype			Total
	GG, <i>n</i> (%)	GA, <i>n</i> (%)	AA, <i>n</i> (%)	
<i>CYP2C9</i> *1/*1	35 (26.7)	30 (22.9)	25 (19.1)	90 (68.7)
<i>CYP2C9</i> *1/*2	11 (8.4)	19 (14.5)	5 (3.8)	35 (26.7)
<i>CYP2C9</i> *1/*3	3 (2.3)	3 (2.3)	—	6 (4.6)
Total	49 (37.4)	52 (39.7)	30 (22.9)	131 (100)

Table 2 lists all of the combinations of the variant genotypes identified in the present cohort study. Of 49 subjects with the *VKORC1* –1639GG genotype, 35 subjects were genotyped as *CYP2C9**1/*1, 11 subjects as *CYP2C9**1/*2, and 3 subjects as *CYP2C9**1/*3. Among the 52 subjects with the *VKORC1* –1639GA genotype, 30 subjects were *CYP2C9**1/*1, 19 subjects were *CYP2C9**1/*2, and 3 subjects were *CYP2C9**1/*3. Among the 30 subjects with the *VKORC1* –1639AA genotype, 25 subjects were *CYP2C9**1/*1, 5 subjects were *CYP2C9**1/*2, and none carried the *CYP2C9**1/*3 genotype.

According to the range of *CYP2C9*- and *VKORC1*-based warfarin dosages suggested by the U.S. FDA [8], 58% of our population (those carrying the genotypes *VKORC1* –1639GG or 1639GA and *CYP2C9**1/*1, or *VKORC1* –1639GG and *CYP2C9**1/*2) would require higher dosages (5–7 mg). In contrast, the remainder of the studied subjects (42%; those carrying the genotypes *VKORC1* –1639GG and *CYP2C9**1/*3, *VKORC1* –1639GA and *CYP2C9**1/*2 or

*CYP2C9**1/*3, or *VKORC1* –1639AA and *CYP2C9**1/*1 or *CYP2C9**1/*2) may require intermediate dosages (3–4 mg). Due to the lack of *CYP2C9**2/*2 or *CYP2C9**3/*3 genotypes and the lack of the combined genotype *VKORC1* –1639AA and *CYP2C9**1/*3, none of the studied subjects belonged to the sensitive group that would require low warfarin dosages (range of 0.5–2 mg).

We also analyzed the data for potential gender differences. However, there were no significant differences in the genotype frequencies of the *CYP2C9**2 and *3 alleles and the *VKORC1* –1639G>A polymorphism in our study group of 131 Saudi Arabian subjects (70 male and 61 female) (data not shown).

Finally, to investigate possible differences between individuals who originated from consanguineous marriages and those who did not, we analyzed the distribution of the *CYP2C9**2 and *3 alleles and the *VKORC1* –1639G>A polymorphism according to this factor. However, the frequencies of the genotypes and alleles studied did not differ with respect to origin from a consanguineous marriage (data not shown).

4. Discussion

The pharmacogenomics of COAs is one field that is most ready to apply genotype-guided dosing in clinical practice. It has been estimated that polymorphisms in the *CYP2C9* and *VKORC1* genes together account for 35%–50% of the variability in COAs initiation and maintenance dosage requirements [20, 40]. Thus, efforts are focused on incorporating this knowledge into the dosing regimens currently used, and genotype-based algorithms are currently being tested in large randomized trials to validate the accuracy, safety, and cost effectiveness of incorporating *CYP2C9* and *VKORC1* genotypes into the optimization of anticoagulant therapy [3, 9].

In the era of developing and testing genotype-guided COAs dosing algorithms, there remain populations in which the frequency of the major *CYP2C9* and *VKORC1* polymorphisms has not been assessed. Thus, potential differences in the prevalence of *CYP2C9* and *VKORC1* genetic variants in different populations may lead to adjustments of genotype-based COAs dosing algorithms or may serve as motivation to identify novel genetic variants that influence COAs therapeutic responses. Towards this goal, the current study reported the frequency of the *CYP2C9**2 and *3 alleles and *VKORC1* –1639G>A polymorphism in a distant population residing on the east coast of Saudi Arabia. Some of the *CYP2C9* variants that lead to decreased enzymatic activity, such as *CYP2C9**5, *6, and *11, were not included in this study because they have not been observed in Caucasian or Middle Eastern populations, in contrast to their higher frequency in African populations. Although consanguineous marriage is traditionally favored among Saudis, genetic inflow in Al-Ahsa is further limited due to social and religious beliefs, which could have led to the differences in the prevalence of the *CYP2C9* and *VKORC1* genotypes and alleles studied.

In general, the genetic characteristics of Arabian populations are not well characterized. In the case of *CYP2C9*,

TABLE 3: Prevalence of *CYP2C9**2 and *3 in different ethnic groups.

Population	N	Allele frequencies of <i>CYP2C9</i>				Ref.
		*2	(P)	*3	(P)	
Middle East Arab						
Saudi (Al-Ahsa)	131	0.133		0.023		Current
Saudi (Riyadh)	192	0.117	0.73	0.091	0.03	[14]
Egyptian	247	0.120	0.87	0.060	0.13	[16]
Jordanian	263	0.135	1.0	0.068	0.09	[25]
Lebanese	161	0.112	0.72	0.096	0.03	[18]
Omani	189	0.074	0.18	0.029	0.72	[17]
Caucasian						
American	100	0.080	0.29	0.060	0.19	[26]
Croatian	200	0.165	0.53	0.095	0.02	[27]
German	118	0.140	0.86	0.050	0.32	[28]
Greek	283	0.129	1.0	0.081	0.03	[13]
Italian	157	0.112	0.86	0.092	0.03	[29]
Turkish	499	0.106	0.54	0.100	0.006	[30]
Belgian	121	0.10	0.56	0.074	0.081	[31]
Asian						
Japanese	218	0	<0.0001	0.021	0.72	[32]
Korean	574	0	<0.0001	0.011	0.22	[33]
Chinese (Mongolian)	280	0	<0.0001	0.03	1.0	[34]
Vietnamese	157	0	<0.0001	0.022	1.0	[35]
Malaysian (Malay)	202	0.019	0.0003	0.024	1.0	[36]
African						
Beninese	111	0	<0.0001	0	<0.0001	[31]
Ethiopian	150	0.04	0.02	0.02	1.0	[29]
Ghanaian	204	0	<0.0001	0	0.06	[37]
Iranian	200	0.13	1.0	0	0.06	[38]
African-American	490	0.011	<0.0001	0.018	0.48	[39]

there are scattered reports on *CYP2C9* frequencies in Arabs in general and Saudis in particular, whereas to the best of our knowledge, this is the first report of the frequency of the *VKORC1* -1639G>A polymorphism in a population in Saudi Arabia. Among Arabs in general, there exists great intraethnic variability in the frequencies of the *CYP2C9**2 and *3 alleles. In Saudi Arabia, Mirghani et al. [14] reported that the frequencies of the *CYP2C9**2 and *3 alleles among Saudis residing in Riyadh were similar to those in Caucasian populations (11.7% and 9.1%, resp.) [14]. Unpredictably, the frequency of *CYP2C9**3 was significantly different from the frequency of *3 in our study group (Table 3). In the Omani population, *CYP2C9**2 and *3 allele frequencies are markedly lower and have been estimated at 7.4% and 2.9%, respectively [17]. The later was the closest Among Arab populations to the frequency of *CYP2C9**3 in our study subjects (2.3%). In the Egyptian population, the frequencies of the *CYP2C9**2 and *3 alleles have been estimated to be 12% and 6%, respectively [16]. In Lebanese individuals, the frequencies of *CYP2C9**2 and *3 have been reported to be 11.2% and 9.6%, respectively [18].

In our study population, the *CYP2C9**2 allele frequency (13.4%) was similar to that reported for other Arabian and

Caucasian populations (Table 3). However, we found a significantly reduced frequency of the *CYP2C9**3 allele (2.3%). In addition, genotypes predicting the *CYP2C9* PM phenotype (i.e., *CYP2C9**2/*2, *CYP2C9**2/*3, and *CYP2C9**3/*3) were absent in the subjects studied. One possible explanation for this finding is that our study population comprised residents of Al-Ahsa, where the population can be divided based on religious beliefs into two main populations (Sunni and Shi-ah) between which intermarriage rarely occurs. Moreover, within each of the two populations, social customs may further limit intermarriage between nonrelatives, further resulting in decreased genetic inflow.

Although we did not find statistically significant differences in the distribution of *CYP2C9**2 and *3 alleles and *VKORC1* -1639G>A polymorphisms in our study group according to presence or absence of consanguineous marriage, different frequencies in variants predicting low *CYP2C9* enzymatic activity should be expected in similar populations elsewhere in Saudi Arabia.

Regarding the *VKORC1* -1639G>A polymorphism, we found that the frequencies of genotypes and alleles were similar to those reported in Caucasian populations. The *VKORC1* -1639AA genotype and *VKORC1* -1639A allele frequencies

were estimated to be 22.9% and 42.7%, respectively, which suggests that approximately 23% of the studied population is sensitive to COAs and would require lower dosages of COAs. However, this finding should not be generalized to all Saudi Arabians prior to assessing the relative genotype frequencies in populations residing in different regions with different social backgrounds. Indeed, we found that the frequency of the *VKORC1* -1639A allele was lower than that reported for other Arabian populations (i.e., 52.4% in the Lebanese population) [18].

The relatively low frequencies of the *CYP2C9**3 allele and *CYP2C9* genotype-derived PMs indicate that, in this population, COAs dosage adjustments and responses may depend more on *VKORC1* gene polymorphisms. This finding is of utmost importance for personalizing COAs therapy in the Al-Ahsa region. The presence of other rare alleles that cause reduced *CYP2C9* activity and could potentially interfere with COAs response requires further investigation. In addition to COAs metabolism, normal to slightly decreased metabolism of other drugs that are *CYP2C9* substrates would be expected in the studied population in addition to the incidence of adverse effects due to diminished metabolism, as is the case with antidiabetic drugs metabolized by *CYP2C9* [41].

In conclusion, we report that the frequency of the *CYP2C9**3 allele varies substantially among Saudi Arabian populations. In light of the frequency of these genetic variants, the *VKORC1* -1639G>A polymorphism may be the major determinant of COAs pharmacogenomics in the studied population. Overall, it appears that some *CYP2C9* genotypes known to be associated with sensitivity to COAs are less common in the studied population, particularly *CYP2C9**3. Investigation of the frequencies of other *CYP2C9* alleles in this population as well as other Saudi populations, especially those variants known to be associated with decreased levels of the *CYP2C9* enzyme, such as *CYP2C9**5, *8, *11, *13-18, *30, and *33, is recommended. To apply COA pharmacogenomics in clinical practice in Saudi Arabia, we need to understand the frequencies of genetic variants in various Saudi Arabian populations in order to facilitate clinical decision making and improve patient management.

Conflict of Interests

The authors declare no competing financial or other conflict of interests.

Acknowledgment

This work was supported by the Deanship of Scientific Research, King Faisal University (Grant no. 130148).

References

- [1] V. G. Manolopoulos, "Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice," *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 7, pp. 801-814, 2007.
- [2] V. G. Manolopoulos, G. Ragia, and A. Tavridou, "Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective," *Pharmacogenomics*, vol. 12, no. 8, pp. 1161-1191, 2011.
- [3] V. G. Manolopoulos, G. Ragia, and A. Tavridou, "Pharmacogenetics of coumarinic oral anticoagulants," *Pharmacogenomics*, vol. 11, no. 4, pp. 493-496, 2010.
- [4] <http://www.cypalleles.ki.se/cyp2c9.htm>.
- [5] H. G. Xie, H. C. Prasad, R. B. Kim, and C. M. Stein, "CYP2C9 allelic variants: ethnic distribution and functional significance," *Advanced Drug Delivery Reviews*, vol. 54, no. 10, pp. 1257-1270, 2002.
- [6] H. Y. Yuan, J. J. Chen, M. T. M. Lee et al., "A novel functional *VKORC1* promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity," *Human Molecular Genetics*, vol. 14, no. 13, pp. 1745-1751, 2005.
- [7] L. Bodin, C. Verstuyft, D. A. Tregouet et al., "Cytochrome P450 2C9 (*CYP2C9*) and vitamin K epoxide reductase (*VKORC1*) genotypes as determinants of acenocoumarol sensitivity," *Blood*, vol. 106, no. 1, pp. 135-140, 2005.
- [8] <http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucml23583.pdf>.
- [9] R. M. F. Van Schie, M. Wadelius, F. Kamali et al., "Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design," *Pharmacogenomics*, vol. 10, no. 10, pp. 1687-1695, 2009.
- [10] B. French, J. Joo, N. L. Geller et al., "Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial," *Trials*, vol. 11, article 108, 2010.
- [11] E. J. Do, P. Lenzini, C. S. Eby et al., "Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design," *Pharmacogenomics Journal*, 2011.
- [12] H. Schelleman, N. A. Limdi, and S. E. Kimmel, "Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics," *Pharmacogenomics*, vol. 9, no. 9, pp. 1331-1346, 2008.
- [13] K. Arvanitidis, G. Ragia, M. Iordanidou et al., "Genetic polymorphisms of drug-metabolizing enzymes *CYP2D6*, *CYP2C9*, *CYP2C19* and *CYP3A5* in the Greek population," *Fundamental and Clinical Pharmacology*, vol. 21, no. 4, pp. 419-426, 2007.
- [14] R. A. Mirghani, G. Chowdhary, and G. Elghazali, "Distribution of the major Cytochrome P450 (*CYP*) 2C9 genetic variants in a Saudi population," *Basic and Clinical Pharmacology and Toxicology*, vol. 109, no. 2, pp. 111-114, 2011.
- [15] J. N. Saour, A. W. Shereen, B. J. Saour, and L. A. Mammo, "CYP2C9 polymorphism studies in the Saudi population," *Saudi Medical Journal*, vol. 32, no. 4, pp. 347-352, 2011.
- [16] S. I. Hamdy, M. Hiratsuka, K. Narahara et al., "Allele and genotype frequencies of polymorphic cytochromes P450 (*CYP2C9*, *CYP2C19*, *CYP2E1*) and dihydropyrimidine dehydrogenase (*DPYD*) in the Egyptian population," *British Journal of Clinical Pharmacology*, vol. 53, no. 6, pp. 596-603, 2002.
- [17] M. O. Tanira, M. K. Al-Mukhaini, A. T. Al-Hinai, K. A. Al Balushi, and I. S. Ahmed, "Frequency of *CYP2C9* genotypes among Omani patients receiving warfarin and its correlation with warfarin dose," *Community Genetics*, vol. 10, no. 1, pp. 32-37, 2007.
- [18] I. Djaffar-Jureidini, N. Chamseddine, S. Keleshian, R. Naoufal, L. Zahed, and N. Hakime, "Pharmacogenetics of coumarin dosing: prevalence of *CYP2C9* and *VKORC1* polymorphisms in the Lebanese population," *Genetic Testing and Molecular Biomarkers*, vol. 15, no. 11, pp. 827-830, 2011.

- [19] L. Yang, W. Ge, F. Yu, and H. Zhu, "Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement—a systematic review and meta analysis," *Thrombosis Research*, vol. 125, no. 4, pp. e159–e166, 2010.
- [20] A. Tavidou, I. Petridis, M. Vasileiadis et al., "Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus," *Diabetes Research and Clinical Practice*, vol. 94, no. 2, pp. 236–241, 2011.
- [21] E. Efrati, H. Elkin, E. Sprecher, and N. Krivoy, "Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population," *Current Drug Safety*, vol. 5, no. 3, pp. 190–193, 2010.
- [22] M. A. F. El-Hazmi, A. R. Al-Swailem, A. S. Warsy, A. M. Al-Swailem, R. Sulaimani, and A. A. Al-Meshari, "Consanguinity among the Saudi Arabian population," *Journal of Medical Genetics*, vol. 32, no. 8, pp. 623–626, 1995.
- [23] B. Weir, "Disequilibrium," in *Genetic Data Analysis II*, M. Sunderland, Ed., pp. 91–139, Sinaur Associates, 1996.
- [24] <http://www.graphpad.com/quickcalcs/contingency1.cfm>.
- [25] A. M. Yousef, N. R. Bulatova, W. Newman et al., "Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population," *Molecular Biology Reports*, vol. 39, no. 10, pp. 9423–9433, 2012.
- [26] T. H. Sullivan-Klose, B. I. Ghanayem, D. A. Bell et al., "The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism," *Pharmacogenetics*, vol. 6, no. 4, pp. 341–349, 1996.
- [27] N. Božina, P. Granić, Z. Lalić, I. Tramišak, M. Lovrić, and A. Stavljenić-Rukavina, "Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population," *Croatian Medical Journal*, vol. 44, no. 4, pp. 425–428, 2003.
- [28] M. Burian, S. Grösch, I. Tegeder, and G. Geisslinger, "Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population," *British Journal of Clinical Pharmacology*, vol. 54, no. 5, pp. 518–521, 2002.
- [29] M. G. Scordo, E. Aklillu, U. Yasar, M. L. Dahl, E. Spina, and M. Ingelman-Sundberg, "Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population," *British Journal of Clinical Pharmacology*, vol. 52, no. 4, pp. 447–450, 2001.
- [30] A. S. Aynacioglu, J. Brockmüller, S. Bauer et al., "Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin," *British Journal of Clinical Pharmacology*, vol. 48, no. 3, pp. 409–415, 1999.
- [31] A. C. Allabi, J. L. Gala, J. P. Desager, M. Heusterspreute, and Y. Horsmans, "Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations," *British Journal of Clinical Pharmacology*, vol. 56, no. 6, pp. 653–657, 2003.
- [32] K. Nasu, T. Kubota, and T. Ishizaki, "Genetic analysis of CYP2C9 polymorphism in a Japanese population," *Pharmacogenetics*, vol. 7, no. 5, pp. 405–409, 1997.
- [33] Y. R. Yoon, J. H. Shon, M. K. Kim et al., "Frequency of cytochrome P450 2C9 mutant alleles in a Korean population," *British Journal of Clinical Pharmacology*, vol. 51, no. 3, pp. 277–280, 2001.
- [34] J. Zuo, D. Xia, L. Jia, and T. Guo, "Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations," *Pharmazie*, vol. 67, no. 7, pp. 639–644, 2012.
- [35] S. S. Lee, K. M. Kim, H. Thi-Le, S. S. Yea, I. J. Cha, and J. G. Shin, "Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population," *Therapeutic Drug Monitoring*, vol. 27, no. 2, pp. 208–210, 2005.
- [36] Z. Zainuddin, L. K. Teh, A. W. M. Suhaimi, and R. Ismail, "Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism," *Journal of Clinical Pharmacy and Therapeutics*, vol. 31, no. 2, pp. 187–191, 2006.
- [37] W. Kudzi, A. N. O. Dodoo, and J. J. Mills, "Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population," *BMC Medical Genetics*, vol. 10, article 124, 2009.
- [38] N. Zand, N. Tajik, A. S. Moghaddam, and I. Milanian, "Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population," *Clinical and Experimental Pharmacology and Physiology*, vol. 34, no. 1-2, pp. 102–105, 2007.
- [39] N. A. Limdi, J. A. Goldstein, J. A. Blaisdell, T. M. Beasley, C. A. Rivers, and R. T. Acton, "Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans," *Personalized Medicine*, vol. 4, no. 2, pp. 157–169, 2007.
- [40] M. Wadelius, L. Y. Chen, J. D. Lindh et al., "The largest prospective warfarin-treated cohort supports genetic forecasting," *Blood*, vol. 113, no. 4, pp. 784–792, 2009.
- [41] G. Ragia, I. Petridis, A. Tavidou, D. Christakidis, and V. G. Manolopoulos, "Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas," *Pharmacogenomics*, vol. 10, no. 11, pp. 1781–1787, 2009.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

